Marker Therapeutics (MRKR) Long-Term Debt Issuances (2010 - 2014)
Marker Therapeutics (MRKR) reported Long-Term Debt Issuances of $41500.0 for Q3 2014, down 94.06% year-over-year from $698261.0 in Q3 2013, and up 109.94% quarter-over-quarter from -$417500.0 in Q2 2014.
Marker Therapeutics (MRKR) Long-Term Debt Issuances (2010 - 2014) Analysis & Trends
Marker Therapeutics (MRKR) has 5 years of Long-Term Debt Issuances data on file, last reported at $41500.0 in Q3 2014.
- Long-Term Debt Issuances for Q3 2014 came in at $41500.0, down 94.06% year-over-year; the trailing twelve-month figure through Mar 2015 was -$376000.0 (down 128.57% YoY), and the FY2014 annual result was $42000.0, down 94.31% from the prior year.
- Long-Term Debt Issuances advanced to $41500.0 in Q3 2014 per MRKR's latest filing, from -$417500.0 in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $698261.0 in Q3 2013 and troughed at -$573333.0 in Q4 2010.
- A 5-year average of $124426.0 and a median of $186529.0 in 2011 frame the typical range for Long-Term Debt Issuances.
- On a YoY basis, Long-Term Debt Issuances climbed as much as 356.21% in 2013 and fell as far as 149.56% in 2013.
- A 5-year view of Long-Term Debt Issuances shows it stood at -$573333.0 in 2010, then surged by 138.37% to $220000.0 in 2011, then surged by 80.0% to $396000.0 in 2012, then sank by 149.56% to -$196261.0 in 2013, then surged by 121.15% to $41500.0 in 2014.
- Business Quant data shows MRKR's Long-Term Debt Issuances at $41500.0 in Q3 2014, -$417500.0 in Q2 2014, and $418000.0 in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | LT Debt Issuance (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 41,500.00 |
| Sep 30, 2014 | 41,500.00 |
| Jun 30, 2014 | -417,500.00 |
| Jun 30, 2014 | -417,500.00 |
| Mar 31, 2014 | 418,000.00 |
| Mar 31, 2014 | 418,000.00 |
| Dec 31, 2013 | -196,261.00 |
| Dec 31, 2013 | -196,261.00 |
| Sep 30, 2013 | 698,261.00 |
| Sep 30, 2013 | 698,261.00 |
| Dec 31, 2012 | 396,000.00 |
| Dec 31, 2012 | 396,000.00 |
| Sep 30, 2012 | 153,058.00 |
| Sep 30, 2012 | 153,058.00 |
| Jun 30, 2011 | 220,000.00 |
| Jun 30, 2011 | 220,000.00 |
| Mar 31, 2011 | 504,535.00 |
| Mar 31, 2011 | 504,535.00 |
| Dec 31, 2010 | -573,333.00 |
| Dec 31, 2010 | -573,333.00 |